期刊文献+

法罗培南钠治疗呼吸道细菌性感染15例 被引量:1

下载PDF
导出
摘要 目的观察法罗培南钠片治疗呼吸道细菌性感染的有效性和安全性。方法采用随机、双盲、双模拟平行对照试验设计,将入选的呼吸道感染患者30例随机分为治疗组和对照组各15例。治疗组给予法罗培南钠片0、2g,po,tid,同时服用头孢克洛模拟胶囊0、25g,tid;对照组给予头孢克洛胶囊0.25g,po,tid,同时服用法罗培南钠模拟片0.2g,tid,疗程均为5~10d。观察两组临床疗效和安全性。结果治疗组和对照组总治愈率分别为50.0%与61.5%,有效率分别为100.0%和92.3%,细菌清除率均为91.7%。治疗组和对照组与药物相关的不良反应发生率均为0。以上结果两组间比较差异无显著性。结论法罗培南钠片治疗呼吸道细菌性感染疗效确切,安全性好。
出处 《医药导报》 CAS 2007年第12期1456-1458,共3页 Herald of Medicine
  • 相关文献

参考文献11

  • 1DALHOFF A, NASU T, OKAMOTO K . Targe taffinities of faropenem to and its impact on the morphology of gram-positive and gram-negative bacteria [ J ]. Chemotherapy, 2003, 49 ( 4 ) : 172 - 183.
  • 2ISHIGURO M, NISHIHARA T, TANAKA R . New orally active penem antibiotic : farom [ J ]. Yakugaku Zasshi, 2001, 121 ( 12 ) : 915 -927.
  • 3BEHRA-MIELLET J, DABREUIL L, BRYSKIER A . In vitro evaluation of faropenem activity against anaerobic bacteria [ J ]. J Chemother, 2005, 17( 1 ) :36 -45.
  • 4WALSH F, AMYES A K, AMYES S G. The in vitro effects of faropenem on lower respiratory tract pathogens isolated in the United Kingdom [J]. Int JAntimicrob Agents, 2003, 21(6):581 -584.
  • 5DATHOFF A, NASU T, OKAMOTO K. Beta-lactamase stability of faropenem [J]. Chemotherapy, 2003, 49(5):229-236.
  • 6NISHIYAMA T, MATSUZAKI K, KOVAMA H, et al. In vitro activity of faropenem against beta-lactamase produing clinicalisolates [J]. Jpn J Antibiot, 2000, 53(3) :179 -183.
  • 7许铁男.青霉烯类抗生素SUN-5555[J].国外医药(抗生素分册),1996,17(1):28-32. 被引量:9
  • 8DAX S L. β-Lactam antibiotics: structure features and SAR of the β-lattain antibiotics [ M ]// Johnson R W Antibacterial chemotherapeutic agent. London, UK: Blackie Academic and Professional, 1997: 128- 130.
  • 9UCHINO H, TAMAI I, YABUUCHI H, et al. Faropenem transport across the renal epithelial luminal membrane via inorganic phosphate transporter Nptl [ J ]. Antimicrob Agents Chemother , 2000, 44 ( 3 ) : 574 - 577.
  • 10MATSUZAKI K, NISHIYAMA T, HASEGAWA M, et al. In vitro bactericidal activities of new oral penem, faxopenem against the various clinical isolates [ J ]. Jpn J Antibiot, 1999, 52 (5) : 431 - 438.

二级参考文献7

  • 1孙小平,黄文祥.青霉烯及其代表药物法罗培南的研究进展[J].国外医药(抗生素分册),2005,26(3):111-115. 被引量:14
  • 2Behra-Miellet J,Dabreuil L,Bryskier A.In vitro evaluation of faropenem activity against anaerobic bacteria[J].J Chemother,2005;17(1):36-45.
  • 3Walsh F,Amyes AK,Amyes SG..The in vitro effects of faropenem on lower respiratory tract pathogens isolated in the United Kingdom[J].Int J Antimicrob Agents,2003;21(6):581-584.
  • 4Dathoff A,Nasu T,Okamoto K.Beta-lactamase stability of faropenem[J].Chemotherapy,2003;49(5):229-236.
  • 5Nishivama T,Matsuzaki K,Kovama H,et al.In vitro activity of faropenem against beta-lactamase produing clinical isolates[J].Jpn J Antibiot,2000;53(3):179-183.
  • 6DalhoffA,Nasu T,Okamoto K.Target affinities offaropenem to and its impact on the morphlogy of gram-positive and gramnegative bacteria[J].Chemotherapy,2003;49(4):172-183.
  • 7Ishiguro M,Nishihara T,Tanaka R.New orally active penem antibiotic:farom[J].Yakugaku Zasshi,2001;121(12):915-927.

共引文献15

同被引文献23

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部